Close

BTIG Remains Neutral on Merrimack Pharma (MACK) Following Q3 Report, Restructuring

November 10, 2016 11:44 AM EST Send to a Friend
BTIG affirms Merrimack Pharma (Nasdaq: MACK) at Neutral following Q3 results and announced restructuring.Analyst Ling Wang commented, Q16 ONIVYDE net ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login